SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-22-005339
Filing Date
2022-12-30
Accepted
2022-12-30 16:29:28
Documents
1

Document Format Files

Seq Description Document Type Size
1 NEOLEUKIN THERAPEUTICS, INC. p22-2717sc13g.htm SC 13G 66358
  Complete submission text file 0000902664-22-005339.txt   68119
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Subject) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-88050 | Film No.: 221502267
SIC: 2834 Pharmaceutical Preparations

Mailing Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607
Business Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

IRS No.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G